The U.S. Food and Drug Administration has approved a labeling change for the widely used blood-thinning drug Coumadin (warfarin).
The Bristol-Myers Squibb Co. of Princeton, N.J., the manufacturer of Coumadin -- as well as manufacturers of warfarin, the generic version of the drug -- will add information to labels explaining a person's genetic makeup might influence how they respond to the drug. Research has shown a person's response to warfarin depends on variants of the genes CYP2C9 and VKORC1.
The FDA said the labeling change highlights the opportunity for healthcare providers to use genetic tests to improve their initial estimate of what is a reasonable warfarin dose for individual patients.
It's estimated about 2 million people start taking warfarin in the United States every year to prevent blood clots, heart attacks and stroke. Warfarin is a difficult drug to use because people taking a dose larger than they can tolerate are at risk of life-threatening bleeding. Those who receive too low a dose are at risk of equally dangerous blood clots.
Warfarin is the second most common drug -- after insulin --implicated in U.S. emergency room visits for adverse drug events.
Copyright 2007 by United Press International
Related stories:
Genetic information makes it safer to prescribe common blood thinner
Doctors prescribing blood thinners have had to go through a lengthy trial-and-error process to arrive at the optimal dose for their patients. But now the process can be faster and safer, thanks to research conducted at Washington University School of Medicine in St. Louis.
Liver damage in hepatitis C patients could be treated with warfarin, says study
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.
Liver damage in Hepatitis C patients could be treated with warfarin, says new study
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.
Pregnancy associated with increased risk of heart attack
Although acute myocardial infarction (AMI) is rare in women of child-bearing age, pregnancy can increase a woman's risk of heart attack 3- to 4-fold, according to a study published in the July 15, 2008, issue of the
Journal of the American College of Cardiology. Since women today may delay having children until later in life, and advances in reproductive medicine enable older women to conceive, the occurrence of AMI associated with pregnancy is expected to increase.
Fewer than 1 in 5 patients receive treatment to prevent life-threatening blood clots
Fewer than 1 in 5 patients received post-discharge therapy to prevent life-threatening blood clots — venous thrombosis — after hip- or knee-replacement surgery, report Rahme and colleagues in a retrospective cohort study. Venous thrombosis is one of the leading causes of death among hospital patients. However, elderly patients have a 70% lower chance of dying within 3 months if they take an anticoagulant drug to prevent blood clots.
Osteoporosis drug fosamax linked to heart problem
Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine.
Genetics determine optimal drug dose of common anticoagulant
Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of
Blood, the journal of the American Society of Hematology. This result represents one of the first applications of using an individual’s genetic information to guide personal medical care.
Women may stop anticoagulants after blood clots
Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor, concludes a study of 646 participants in a multicentre prospective cohort study.